Cargando…

The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout

OBJECTIVE: To measure the effect of febuxostat on the serum levels of uric acid (sUA) and the proinflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-α (TNF-α) in Chinese Han patients with gout and hyperuricaemia. METHODS: This randomized, double-blind, placebo-controlled pilo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yuan-Yuan, Ye, Zhuang, Gu, San-Wei, Jiang, Zhen-Yu, Zhao, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Prospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221481/ https://www.ncbi.nlm.nih.gov/pubmed/32363973 http://dx.doi.org/10.1177/0300060520902950

Ejemplares similares

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Plasma P-selectin level is associated with severity of coronary heart disease in Chinese Han population
por: Song, Chunhui, et al.
Publicado: (2020)

Elevated alanine aminotransferase is associated with biphasic insulin secretion in the healthy elderly Han Chinese population
por: Wu, Tzong-Yow, et al.
Publicado: (2022)

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
por: Suzuki, Satoshi, et al.
Publicado: (2021)

Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial
por: Jia, Ertao, et al.
Publicado: (2021)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
por: Kamel, Bishoy, et al.
Publicado: (2022)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study
por: Shiramoto, Masanari, et al.
Publicado: (2018)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population
por: Li, Zhiqiang, et al.
Publicado: (2017)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

New formula for predicting standard liver volume in Chinese adults
por: Feng, Ling-Mei, et al.
Publicado: (2017)

Genetic association of polymorphism rs2230054 in CXCR2 gene with gout in Chinese Han male population
por: WANG, YANGANG, et al.
Publicado: (2020)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
por: Lee, Joondon, et al.
Publicado: (2023)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Low-pressure pneumoperitoneum with abdominal wall lift in laparoscopic total mesorectal excision for rectal cancer: Initial experience
por: Xia, Ping-Tian, et al.
Publicado: (2018)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
por: Frassetto, Lynda Ann, et al.
Publicado: (2016)

Effects of Febuxostat in Early Gout: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat
por: Sheer, Richard, et al.
Publicado: (2017)

Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis
por: Zhang, Zheng, et al.
Publicado: (2020)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
por: Zhang, Peiyu, et al.
Publicado: (2022)

The Clinical Effects of Febuxostat Alone or Combined with Arthroscopic Surgery for Gout: A Single-Center Retrospective Study
por: Gong, Zhen, et al.
Publicado: (2021)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
por: Jeong, Hoon, et al.
Publicado: (2022)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
por: van Leeuwen, Kevin D. B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_apas8h92iigugq6rmdg8m39s78